Ovarian cancer is the leading cause of death from gynaecological cancer in the UK, although survival rates have improved in recent decades, there are still more deaths from ovarian cancer than all other gynaecological cancers combined. Surgery with chemotherapy is one of the main treatments for ovarian cancer and cell salvage is already used successfully in other types of surgery. In this it is not known whether donor blood transfusion or cell salvage transfusion is better for patients undergoing ovarian cancer surgery, or which method provides better value for money. This study was conducted to help us to answer these questions.
The National Institute for Health Research (NIHR) funded trial recruited 57 participants from across four sites; Royal Cornwall Hospitals Trust (Sponsors of the trial), Gateshead Health NHS Foundation Trust, University Hospitals Plymouth NHS Trust and Leicester Royal Infirmary.
Khadra Galaal, Consultant Gynaecological Oncologist & Chief Investigator (pictured below), would like to thank all patients involved as well as the health care professional colleagues from across the four NHS sites and the University of Plymouth Peninsula Clinical Trials Unit (www.plymouth.ac.uk/penctu) for their hard work in ensuring the success of this trial.
The results of this feasibility study will form the basis of a funding application for a large Randomised Controlled Trial